Voting Rights and Shares Capital of the Company
Rhea-AI Summary
Nanobiotix (Nasdaq: NBTX) published its voting rights and shares capital figures as of March 31, 2026. The company reports 48,517,630 shares outstanding and total voting rights of 50,165,132 (theoretical) and 50,143,014 (exercisable).
Listings: Euronext Paris (Compartment B) and Nasdaq. ISIN: FR0011341205.
Positive
- None.
Negative
- None.
News Market Reaction – NBTX
In the Apr 8 session, NBTX gained 2.22%, reflecting a moderate positive market reaction. Argus tracked a trough of -6.3% from its starting point during tracking. Our momentum scanner triggered 5 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Mar 31 | Full-year results | Positive | +10.4% | Improved 2025 financials and clinical progress, narrower net loss and solid cash. |
| Mar 30 | Clinical data update | Positive | +2.1% | Phase 2 lung cancer data with acceptable safety and strong initial efficacy metrics. |
| Mar 26 | Earnings date notice | Neutral | -4.4% | Announcement of timing for Q4 and full-year 2025 results and conference call. |
| Mar 25 | Takeover clarification | Negative | +4.7% | Company denied any ongoing takeover process and corrected media speculation. |
| Mar 12 | Voting rights update | Neutral | +4.9% | Disclosure of shares outstanding and theoretical versus exercisable voting rights. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent NBTX news, especially earnings and clinical updates, often coincided with positive price reactions, while neutral or clarifying disclosures showed mixed or divergent moves.
Over the past month, Nanobiotix issued multiple updates: a strong full‑year 2025 report on Mar 31, 2026 with narrowed net loss and solid cash supported a 10.37% gain; encouraging Phase 2 lung cancer data on Mar 30 coincided with a 2.10% rise. Earlier, an earnings‑date announcement on Mar 26 and a media‑speculation rebuttal on Mar 25 produced mixed moves. A prior voting‑rights disclosure on Mar 12 saw a 4.92% increase, suggesting investors watch capital-structure details.
Key Terms
isin code financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
In accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers)
PARIS, April 07, 2026 (GLOBE NEWSWIRE) --
Market: Euronext Paris / Nasdaq
Euronext Compartment: B
ISIN code: FR0011341205
Nasdaq: NBTX
Bloomberg: NANO:FP
Reuters: NANO.PA
Website: www.nanobiotix.com
| Date | Number of Shares Outstanding | Total number of voting rights | |
| Total voting rights, theoretical1 | Total voting rights, exercisable2 | ||
| March 31, 2026 | 48,517,630 | 50,165,132 | 50,143,014 |
About NANOBIOTIX
Nanobiotix is a late-stage clinical biotechnology company pioneering disruptive, physics-based therapeutic approaches to revolutionize treatment outcomes for millions of patients; supported by people committed to making a difference for humanity. The Company’s philosophy is rooted in the concept of pushing past the boundaries of what is known to expand possibilities for human life.
Incorporated in 2003, Nanobiotix is headquartered in Paris, France and is listed on Euronext Paris since 2012 and on the Nasdaq Global Select Market in New York City since December 2020. The Company has a subsidiary in Cambridge, Massachusetts (United States).
Nanobiotix is the owner of more than 30 patent families associated with three (3) nanotechnology platforms with applications in 1) oncology; 2) bioavailability and biodistribution; and 3) disorders of the central nervous system.
For more information about Nanobiotix, visit us at www.nanobiotix.com or follow us on LinkedIn and Twitter.
________________________
1 The total number of theoretical (or “gross”) voting rights is used as the basis for calculating threshold crossings. In accordance with Article 223-11 of the AMF General Regulations, this number is calculated on the basis of all shares to which voting rights are attached, including those for which voting rights have been suspended.
2 The total number of exercisable at a shareholders’ meeting (or “net”) voting rights is calculated without taking into account shares for which voting rights have been suspended as shares held in treasury by the Company. It is released in order to ensure that the public is properly informed.
Contacts
| Nanobiotix | |
Communications Department Brandon Owens VP, Communications +1 (617) 852-4835 contact@nanobiotix.com | Investor Relations Department Joanne Choi VP, Investor Relations (US) +1 (713) 609-3150 Ricky Bhajun Director, Investor Relations (EU) investors@nanobiotix.com |
| Media Relations | |
France – HARDY Caroline Hardy +33 06 70 33 49 50 carolinehardy@outlook.fr | Global – uncapped Becky Lauer +1 (646) 286-0057 uncappednanobiotix@uncappedcommunications.com |
Attachment
- 2026-04-07 -- NBTX -- Voting Rights & Shares Capital -- FINAL
